EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)

Yasuhiko Matsumori, Hiroshi Yamada, Yoshishige Nagaseki, Kazutaka Shimizu, Krisztian Nagy iD, Ryotaro Matsuzawa, Tetsuya Otani, Molly Yizeng He, Hua Guo, Gina Ahmadyar iD, Takao Takeshima

Cephalalgia · 2025

DOI: 10.1177/03331024251374569 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2025. Verfasst von Yasuhiko Matsumori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists, Dipeptides, Quinazolines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved in the US and EU for the preventive treatment of migraine in adults. We evaluated the efficacy, safety, and tolerability of atogepant for the preventive treatment of episodic migraine (EM) in Japanese participants.

Methods

RELEASE was a phase 2/3, multicenter, randomized, double-blind, placebo-controlled study enrolling adult participants with a ≥1-year history of migraine,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsDipeptidesQuinazolinesHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedTreatment OutcomeYoung AdultJapanDose-Response Relationship, DrugPyrrolesPiperidinesSpiro CompoundsPyridinesEast Asian People

Stichwörter der Autor:innen

AtogepantJapanepisodic migrainerandomized-controlled trial

Substanzen

atogepantCalcitonin Gene-Related Peptide Receptor AntagonistsDipeptidesQuinazolinesPyrrolesPiperidinesSpiro CompoundsPyridines

Autor:innen und Institutionen

  • Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan.
  • Umenotsuji Clinic, Kochi, Japan.
  • Nagaseki Headache Clinic, Yamanashi, Japan.
  • Tokyo Headache Clinic, Tokyo, Japan.
  • AbbVie, North Chicago, IL, USA.
  • AbbVie GK, Tokyo, Japan.

ORCID-Profile: Krisztian Nagy, Gina Ahmadyar

Förderung

  • AbbVie

Zitieren

APA

Matsumori, Y., Yamada, H., Nagaseki, Y., Shimizu, K., Nagy, K., Matsuzawa, R., Otani, T., He, M. Y., Guo, H., Ahmadyar, G., & Takeshima, T. (2025). Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. https://doi.org/10.1177/03331024251374569

Vancouver

Matsumori Y, Yamada H, Nagaseki Y, Shimizu K, Nagy K, Matsuzawa R, et al. Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025. doi:10.1177/03331024251374569

BibTeX
@article{Matsumori2025,
  author = {Matsumori, Yasuhiko and Yamada, Hiroshi and Nagaseki, Yoshishige and Shimizu, Kazutaka and Nagy, Krisztian and Matsuzawa, Ryotaro and Otani, Tetsuya and He, Molly Yizeng and Guo, Hua and Ahmadyar, Gina and Takeshima, Takao},
  title = {Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251374569}
}
Kostenlos starten →